Agilent picks IBM for data search


Agilent picks IBM for data search

Agilent Technologies has selected IBM's DiscoveryLink data integration software to anchor its Synapsia bioinformatics product family.

DiscoveryLink has been made compatible with Agilent's Synapsia, software for the pharmaceutical market, IBM spokeswoman Theo Chisholm said.

DiscoveryLink, based on IBM's DB2 database, allows researchers to query diverse data sources in research terminology and get a result in a single format, leaving the underlying databases intact. DiscoveryLink also searches databases running software from IBM rivals Oracle and Sybase.

"In this research environment there is more data then ever before, coming from multiple sources and increasing in size rapidly. DiscoveryLink gives customers the data integration component they will need," Chisholm said.

Synapsia provides a single environment for documentation of information related to a research project, and enables multidisciplinary scientists to work together and share their interpretation of data, Agilent said.

The software is designed to allow visual analysis and filtering of data and creation of compound-centric models. The combination of DiscoveryLink and Synapsia software aims to help users connect disparate information sources.

Users of Agilent's scientific instruments will have to buy it from IBM, although that should not be too much of a problem, because Agilent customers often call on IBM for supercomputer and database needs, Chisholm said. IBM and Agilent will work together to implement the products.

DiscoveryLink for Agilent's Synapsia products is available worldwide. Pricing depends on the customer situation.

Email Alerts

Register now to receive IT-related news, guides and more, delivered to your inbox.
By submitting your personal information, you agree to receive emails regarding relevant products and special offers from TechTarget and its partners. You also agree that your personal information may be transferred and processed in the United States, and that you have read and agree to the Terms of Use and the Privacy Policy.

COMMENTS powered by Disqus  //  Commenting policy